Gilead Sciences (GILD)

Gilead deal and 2028 cash runway frame upcoming hepatitis data.

Gilead Sciences increased its quarterly dividend by 3.8% this year.

Vir Biotechnology (NASDAQ:VIR) expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 2027, executives said on the company’s third-quarter earnings call. The company

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Wednesday afternoon. Here’s what to expect. Myriad Genetics mi...

Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here’s what you need to know. Amgen beat analysts’ revenue exp...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. Bio...

The company is having a great year.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year...

Base business sales surged 16%, marking strongest growth in over a decade.

Gilead Sciences (NASDAQ:GILD) reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove performance. The company also raised its full-year base business revenue outlook while outlining t

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.8% year on year to $8.3 billion...

Gilead Sciences crushed Wall Street's sales expectations on the back of its HIV treatments and cancer drug Trodelvy.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after the bell. Here’s what you need to know. Gilead Sciences...

BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.

These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

Both of these biotech stocks could be appealing to income investors.